(Q46245586)

English

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Plasmodium vivax

0 references

Christopher B Fox

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Jetsumon Sattabongkot

4

object named as

Jetsumon Sattabongkot

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

8

object named as

Steven G Reed

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Christian F Ockenhouse

9

object named as

Christian F Ockenhouse

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

author name string

Joanne M Lumsden

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Saule Nurmukhambetova

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Jennifer H Klein

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Jason W Bennett

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Sylvie Bertholet

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Randall F Howard

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Mark E Polhemus

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

Anjali Yadava

12

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

language of work or name

0 references

publication date

13 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

30

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

22

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

3311-3319

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Resiquimod and other immune response modifiers as vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Sporozoites of mammalian malaria: attachment to, interiorization and fate within macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Invariant Valpha14 chain NKT cells promote Plasmodium berghei circumsporozoite protein-specific gamma interferon- and tumor necrosis factor alpha-producing CD8+ T cells in the liver after poxvirus vaccination of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

T-cell quality in memory and protection: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.004

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.03.004

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/22425788

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46245586&oldid=2102103658"